In8bio (INAB) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

INAB In8bio

Watchlist

0.342
-0.026-7.15%

Trading Dec 3 10:00 ET

24.77MMarket Cap-461P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
GlobeNewswireDec 2 07:00 ET
Analysts Offer Insights on Healthcare Companies: IN8bio (INAB), Vigil Neuroscience Inc (VIGL) and Outlook Therapeutics (OTLK)
TipRanksNov 28 09:40 ET · Ratings
Mizuho Securities Remains a Buy on IN8bio (INAB)
TipRanksNov 27 01:16 ET
JonesTrading Maintains In8bio(INAB.US) With Hold Rating
Moomoo NewsNov 26 10:32 ET · Ratings
IN8Bio Presented Results From The Fully Enrolled Phase 1 Trial Of INB-200 At The Annual Meeting Society For Neuro-oncology
BenzingaNov 25 07:08 ET
Express News | IN8bio Reports Continued Durable Remissions in Phase 1 Trial of Inb-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (Sno) Annual Meeting
ReutersNov 25 07:00 ET

Comments

Jaguar8

Nov 25 06:06

NEWS

$In8bio (INAB.US)$
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting
IN8bio presented results from their fully enrolled Phase 1 trial of INB-200 at the Society for Neuro-Oncology Annual Meeting. 50% of patients receiving repeated doses (n=10) remained alive and in remission beyond expected median overall survival, while single-dose patients (n=3) did not achieve this outcome. The trial de...